Broad selling pressure keeps Hims & Hers stock restrained after telehealth expansion news

Traders Union
All News
Financial News
Hims & Hers drops 3.28% today

Highlights

Hims & Hers has expanded its digital health platform by adding Novo Nordisk weight-loss solutions, advancing its telehealth growth strategy.
This rollout builds on the company's earlier introduction of a GLP-1 subscription service, signaling a deeper push into prescription obesity treatments.
HIMS trades under sustained selling pressure below key resistance, with technical signals favoring a sideways or bearish move within the $18.80 to $20.10 range.

Telehealth expansion efforts face market skepticism despite new product launch

Hims & Hers launched Novo Nordisk weight-loss solutions on its platform, following recent product expansion efforts. This new addition is part of the company's broader strategy to enhance its telehealth offerings, including the earlier announcement of a GLP-1 subscription service. The product rollout comes amid ongoing developments in digital health services, though price action has remained under broader selling pressure.

Downtrend momentum holds as multiple indicators flag weakness

Momentum signals remain weak, with the MACD showing a neutral setup, while the ADX D1 indicates a persistent downtrend. The RSI stands at 45.47 on the daily timeframe and 37.18 weekly, both within the sell zone. CCI is neutral but near oversold, and Stoch RSI oscillates between oversold and neutral intraday. BBP indicates an overbought condition on the daily, but switches to oversold across shorter intervals, hinting at seller dominance during intraday moves. Price action reveals a session that opened lower, currently sitting mid-range after a gap down, with moderate intraday volatility and the tone remaining pressured.

Sideways movement favored as trend signals limit bullish scenarios

For the next five sessions, HIMS is likely to trade within a volatility band between $18.80 and $20.10. There is a very low probability — less than 20% — of a price increase, as major weekly trend indicators are not signaling a buy. The baseline scenario is for HIMS to move sideways between recent support and resistance. A sustained move above $20.93 would be required for a bullish reversal, while a break below intraday lows could lead to further declines toward $18.80.

Viktoras Karapetjanc, expert at Traders Union, sees the recent product expansion as a solid move for Hims & Hers Health Inc, improving long-term fundamentals despite near-term selling pressure. He notes that the broader digital health trend and the introduction of Novo Nordisk solutions strengthen the company’s strategic position. However, sideways price action and weak momentum limit upside for now. Positive sentiment could return if the price breaks above $20.93. "As long as HIMS holds above key support and continues expanding its offerings, I remain cautiously constructive on its prospects in the coming sessions."

Earlier, analysts noted that Hims & Hers was experiencing persistent selling pressure despite positive product rollouts. The current analysis reinforces this bearish outlook, with sustained weakness across technical indicators suggesting that traders should closely monitor the risk of further declines if the stock fails to hold above $18.80 in the coming sessions.

Source of Data: HIMS Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.